e-ISSN: 2618-0979     print ISSN: 2618-0960
Using of drug “Ropren” in the treatment of herpes simplex
##common.pageHeaderLogo.altText## Journal of Theoretical, Clinical and Experimental Morphology

Abstract

Viral dermatoses caused by simple herpes viruses (HSV-I, II) are the most widespread, chronic and recurrent diseases in the world. Dermatoneinrotropic HSV-I, II DNA-containing viruses. Currently, acyclic nucleosides (aciclovir, valaciclovir) are used primarily in the treatment of simple herpes. Although these drugs stop replication of viruses, they can not prevent recurrences. Ropren may also be administered in parallel to treatment with an immunomodulatory effect to prevent relapses and increase remission.

References

Van der Linden MW, Westert GP, De Bakker DH, Schellevis FG. Second national study into diseases and actions in general practice. Utrecht, Bilthoven: Netherlands Institute for Health Services Research (NIVEL), National Institute of Public Health and the Environment (RIVM); 2004.

Embil JA, Stephens RG, Manuel FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J. 1975;113(7):627–30.

Sparano JA, Sarta C. Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy. Curr Opin Oncol. 1996;8(5):392–9. [PubMed]

Scoular A, Norrie J, Gillespie G, Mir N, Carman WF. Longitudinal study of genital infection by herpes simplex virus type 1 in Western Scotland over 15 years. BMJ. 2002;324(7350):1366–7.

5. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med. 1987;316(23):1444–9.

Corey L, Handsfield HH. Genital herpes and public health: addressing a global problem. JAMA. 2000;283(6):791–4.

7. Ross JD, Smith IW, Elton RA. The epidemiology of herpes simplex types 1 and 2 infection of the genital tract in Edinburgh 1978–1991. Genitourin Med. 1993;69(5):381–3.

Wheeler CE., Jr The herpes simplex problem. J Am Acad Dermatol. 1988;18(1 Pt 2):163–8.

Esmann J. The many challenges of facial herpes simplex virus infection. J Antimicrob Chemother. 2001;47(Suppl T1):17–27.

Straus SE, Rooney JF, Sever JL, Seidlin M, Nusinoff-Lehrman S, Cremer K. NIH Conference. Herpes simplex virus infection: biology, treatment, and prevention. Ann Intern Med. 1985;103(3):404–19.

Opstelten W. In: Stomatitis herpetica. [Minor ailments in children.] Eekhof JAH, Knuistingh Neven A, Verheij TJM, editors. Maarssen, The Netherlands: Elsevier; 2005. pp. 273–5.

Godfrey HR, Godfrey NJ, Godfrey JC, Riley D. A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine. Altern Ther Health Med. 2001;7(3):49–56.

Kneist W, Hempel B, Borelli S. [Clinical double-blind trial of topical zinc sulfate for herpes labialis recidivans] Arzneimittelforschung. 1995;45(5):624–6.

PDF (Azərbaycanca)
PDF (Azərbaycanca)

Keywords

Ropren
acyclic nucleosides
aciclovir
valaciclovir Ропрен
ациклические нуклеозиды
асикловир
валасикловир “Ropren” preparatı
asiklik nukleozidləri
asiklovir
valasiklovir